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Abstract
To realize the full potential of next-generation sequencing, it is important to consider multiple sources of genetic
information, including inheritance, association, and bioinformatics. To illustrate the promise of such an approach, we
applied our next-generation linkage and association (NGLA) methods to the sequence data of a large 57-member
Mexican American family with hypertension. Our results show that OSBPL10–a disease susceptibility gene for
dyslipidemia–may also influence systolic blood pressure (SBP). In particular, our NGLA dense single-nucleotide
polymorphism (SNP) analysis identified a 2.5-megabase (Mb) region that strongly cosegregates with low SBP
(maximum posterior probability of linkage [PPL] = 68%). Furthermore, using the posterior probability of linkage
disequilibrium (PPLD), we fine-mapped this region and identified 12 SBP-associated variants (PPLD ranging between
4% and 14%) that comprise a rare, 4-site haplotype. This haplotype extends into the candidate gene, OSBPL10
(oxysterol-binding protein-like 10). In contrast to our NGLA methods, a commonly used filter-based approach
identified 23 variants with little evidence for spatial clustering around any particular gene or region of interest.
Background
The Genetic Analysis Workshop 18 (GAW18) distributed
phenotype, genotype, and sequence data on 20 large
Mexican American families. For 772 individuals who
were not taking medication for hypertension, SBP was
measured repeatedly with a maximum of 4 observations
per person. Eighty-four individuals were actively taking
hypertension medication, and the phenotypes of 530
individuals were unobserved. For individuals who were
not taking medication for hypertension, we used SBP at
the first available time point as our quantitative pheno-
type and regarded treated individuals (ie, those taking
hypertension medication) as affected. All analyses were
performed on the unadjusted phenotype data without
correction for covariates, and, as recommended by the
GAW18 Program Committee, we restricted our attention
to chromosome 3.
Methods
We analyzed the phenotypic data under a quantitative trait
threshold model using the program KELVIN [1], which
integrates out all parameters of the trait model, including
the threshold parameter. Therefore, with this model, the
SBP values of untreated individuals were analyzed jointly
with the affected status of treated individuals. When the
quantitative trait threshold model is used in conjunction
with a model for the observed genotypes, the probabilities
of linkage and linkage disequilibrium (LD) can be com-
puted without fixing the parameters of the trait model.
However, if desired, estimates of these parameters (ie, pos-
terior means) are easily obtained as a by-product of the
calculations required for the PPL. To mitigate the negative
effects of genotyping error, we applied standard quality-
control procedures. As a result, SNPs with minor allele
frequencies less than 0.01 and SNPs with Hardy-Weinberg
equilibrium p values less than 0.0001 were removed.
To maximize the chance of detecting linkage, we ana-
lyzed all 20 families across a relatively sparse, but highly
informative subsample of the 65,519 genome-wide
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association study (GWAS) SNPs. In particular, the
selected subsample contained 719 SNPs with an average
heterozygosity of 43% and a maximum pairwise r2
between adjacent SNPs of 0.20. The genetic map was
obtained from the Rutger’s published map [2], and the
PPL was computed using KELVIN. The pedigree-based
likelihoods for the very large families were computed
using a novel hybrid Markov chain Monte Carlo
(MCMC) approach. Specifically, the MCMC handled the
genotype data [3], while a fast and accurate adaptive
quadrature method handled the phenotype data [4]. As
a precaution, we also used the program EAGLET [5,6]
in conjunction with LM_MARKERS [7] to assess the
evidence for linkage. Note that EAGLET generates mul-
tiple random, informative subsamples from dense SNP
genotype data, and that LM_MARKERS estimates
model-based pedigree likelihoods for large families.
Therefore, the coordinated use of both programs pro-
vides inference about cosegregation that is robust to
linkage map construction.
To identify SBP susceptibility genes (ie, to fine-map
underneath a linkage peak), we selected the pedigree
with the largest PPL on chromosome 3 and applied our
NGLA methods to the sequence data of a 2.5 Mb region
covering the peak. These methods include (but are not
limited to) a bayesian approach to linkage analysis (eg,
PPL), dense SNP linkage analysis (eg, EAGLET), general-
ized association analysis with both family-based and
population-based components (eg, PPLD), and standard
techniques in bioinformatics. As such, we extracted all
sequence variants in the region, and computed the PPLD
for the 9263 sequence variants observed in this family.
To compare our methods to a commonly used filter-
based approach (FBA) we:
1. Filtered out all common variants (ie, minor allele
frequency ≥0.01) from the 1,215,400 total variants of
chromosome 3.
2. Selected distant relatives (n = 3) over the age of 31
years with low SBP.
3. Filtered out variants that were not shared by the
distant relatives in (2).
4. Used a phastCons 44-way threshold of 220 [8] to
prioritize the variants that could not be filtered out by
(1) and (3).
We performed the FBA analysis based on low SBP
because the estimated trait model from the linkage ana-
lysis indicated that the locus would be protective against
high SBP.
Results
Of the 20 large Mexican American families, we focused
on Ped15, which is the family with the strongest evidence
for linkage (Figure 1; maxPPL = 68%; Bayes factor =
104.125). The linkage peak occurred at 54 centimorgans
(cM) (Figure 2) and provided a narrow 4-cM region (52
cM, 56 cM) in which to follow-up with fine-mapping via
the PPLD. In addition, we used EAGLET, LM_MAR-
KERS, and a fixed trait model to compute the maximum
of the average log of odds (LOD) score (2.43), where the
average was taken over 15 random subsamples. More-
over, the 4-cM region identified by the PPL is completely
contained within the EAGLET-based support interval
(52.0, 62.9). The qualitative agreement between EAGLET,
which is robust to the SNP selection procedure, and the
PPL suggests that our PPL-based results are unlikely to
be biased by the linkage map construction.
To fine-map the 4-cM region of interest, we applied
the PPLD to all 9263 sequence variants. Note that in this
region, 1059 of the GWAS SNPs are also present in the
sequence data. The highest PPLD is 14% at variant
3_31907631, and the complete list of variants with PPLD
scores greater than or equal to 4% is shown in Table 1.
Note that the PPLD assumes a prior probability of LD =
0.04%, so that the seemingly low posterior probability of
4% is, in fact, a 100-fold increase over the prior probabil-
ity of LD. Also recall that we are considering LD within a
single family with just 18 founders. Variant 3_31590155
is located in a highly conserved intron (phastCons 44-
way score = 294) of OSBPL10–a lipid receptor and
potential candidate gene for high blood pressure [9]. In
addition, this variant contributes to the rare 4-site haplo-
type (Table 1) that (a) only appears in families 4 and 15,
and (b) lies directly beneath the PPL peak (see Figure 2).
Also, note that family 4 provides some evidence for link-
age at this locus (maximum PPL = 7%). Finally, to com-
pare our NGLA methods to a commonly used FBA, we
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carried out the 4-step filtering procedure described in
Background above. Similar to our NGLA methods, FBA
identified variant 3_31590155. However, FBA also found
22 other variants spread across the entire chromosome
(see Figure 2). Interestingly, rs7624739 (PPLD = 14%)
was missed by FBA, and because it is not among the
GWAS SNPs, it would also have been missed in a gen-
ome-wide association analysis.
Discussion
It is important to remember that although our metho-
dology-related results should be generalizable, our SBP-
related results are primarily of a preliminary nature.
Therefore, before any biological conclusions are drawn,
the following caveats should be considered. First, the
sequence data for Ped15 were entirely imputed. Ideally,
the quality of that imputation–especially the existence
Figure 2 The PPL for Ped15 and sequence variants prioritized by NGLA (black dot) and FBA (gray dots). The dashed line is the prior probability
for linkage
Table 1 Characteristics of sequence variants identified by NGLA methods
Variant Minor allele MAF PPLD SNP Intronic OSBPL10 Comment
3_30813267 G 0.3790 0.04 Y N
3_30833347 T 0.2115 0.04 Y N
3_30836121 A 0.2196 0.04 Y N Is also 1 of 65,519 GWAS SNPs
3_30836281 A 0.2169 0.04 Y N
3_30836986 T 0.2196 0.04 Y N
3_30837454 G 0.2246 0.04 Y N
3_30839168 G 0.2159 0.04 Y N
3_31367917 A 0.0017 0.04 N N Appears only in families 4 &15
3_31590155 A 0.0017 0.04 N Y Appears only in families 4 &15
3_31688599 A 0.0017 0.04 Y Y Appears only in families 4 &15
3_31773725 C 0.0017 0.04 N Y Appears only in families 4 &15
3_31907631 A 0.0729 0.14 Y Y AKA rs7624739
MAF, minor allele frequency.
Sequence variants 3_31367917,3_31590155,3_31688599, and 3_31773725 (in bold) form a rare 4-site haplotype that strongly segregates with low SBP.
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and segregation of the 4-site haplotype–should be veri-
fied experimentally in the lab. Second, we did not adjust
for measured covariates, which may have influenced
some part (or all) of our results. Third, we confined our
analyses to a 4-cM region of chromosome 3, which
means that candidate genes in other regions (eg, MAP4
at 69 cM) cannot be excluded. As such, candidate genes
in these regions deserve further investigation. Also, to
the extent possible, we examined the sensitivity of our
methods to MCMC error and to different phenotype
definitions. In each case, our conclusions remained qua-
litatively the same.
Our NGLA approach to the analysis of sequence data
led us to a manageable number of intronic (and inter-
genic) variants that lie in an excellent candidate gene:
OSBPL10. Furthermore, the 4-site rare haplotype that we
identified, was not seen in any of the unlinked families,
but was seen in one of the other linked families.
Although the commonly used FBA identified OSBPL10,
it missed the strongest PPLD association: 3_31907631
(rs7624739), and it found several variants in apparently
unlinked regions of chromosome 3 (PPL <2%).
Conclusions
In summary, our methods have particularly nice features,
including the posterior probability paradigm which is
robust to trait model uncertainty; inherently ascertain-
ment corrected; yields accurate localization given a dense
marker map; returns a posterior probability rather than a
p value; detects linkage (PPL) and association (PPLD);
and, in this case, permits the simultaneous use of both
quantitative (SBP) and dichotomous phenotypic informa-
tion (ie, individuals affected with hypertension). Our
approach also gives researchers the opportunity to make
efficient use of all of the available dense SNP data, and
permits the use any existing linkage analysis method that
can handle multipoint analysis of dense SNP data in large
pedigrees (eg, LM_MARKERS [7], SOLAR [10], etc).
Therefore, if one restricts attention to the sequence data
of a single large family, or if one studies multiple families,
our NGLA methods provide excellent opportunities to
map disease loci and to fine-map individual genes down
to a handful of potentially pathogenic variants.
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